|
|
Post by boca1girl on Jun 7, 2019 12:38:37 GMT -5
Mango, can you explain these in simple English? Thanks.
|
|
|
|
Post by prcgorman2 on Jun 9, 2019 20:54:07 GMT -5
I don't think that would work. Has there ever been an instance of a pharma charging people to administer their drug beyond the cost of the drug? That seems like it would be counter-productive. Yes, there have been examples of that but it is a horrible business practice that doesn't work in the real world. This is a "methods" patent which restricts how a drug can be used, but the only people who can infringe on the patent are physicians. Besides the difficulty of identifying every infringer out there, bringing a lawsuit against the relatively few customers that are actually using your product is not prominently featured in the book "How to Win Friends and Influence People". What it does do is prevent competitors from using the idea in their marketing materials but even that is of questionable value as a methods patent does not prevent medical journals from describing the method. Could a Fiasp salesperson hand out copies of a medical journal describing the method? You bet. I will caution about being fixated on patents as ways to prevent competitors from doing something without licensing on a “Fair, Reasonable, and Non-Discriminatory” basis. Patents are also used defensively to prove competence in a body of work. There can be tweaks on a patent for that purpose. Ordinarily I would just recommend asking someone at Mannkind what was the purpose or intent of the new patent, but since so much material gets reprinted on social media (and who knows if there is editorializing), I wouldl not be surprised if Mannkind simply said, “No comment”. |
|
|
|
Post by mango on Jun 16, 2019 16:11:21 GMT -5
New International MannKind Patent Application Published 6/13/2019 DRY POWDER INHALER AND SYSTEM FOR DRUG DELIVERYAbstract:A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with the inhaler. The inhaler and/or cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin, oxyntomodulin and glucagon-like peptide. Applicants: MannKind Corporation Inventors: Chad C. Smutney P. Spencer Kinsey Carl R. Sahi Benoit Adamo John M. Polidoro Scott McLean Dennis Overfield Anthony Bryant patentscope.wipo.int/search/en/detail.jsf?docId=US243316588&tab=NATIONALBIBLIO&office=&prevFilter=&sortOption=Pub+Date+Desc&queryString=FP%3A%28MannKind%29&recNum=1&maxRec=1153 |
|
|
|
Post by brotherm1 on Jun 16, 2019 20:40:43 GMT -5
“International” seems to be the operative word. Nice
|
|
|
|
Post by mnkdfann on Jun 16, 2019 20:53:24 GMT -5
New International MannKind Patent Application Published 6/13/2019 Patents are not my thing. How do you know it is 'International'? The text at one of the tabs says: "This application is a continuation of U.S. patent application Ser. No. 13/933,813, filed Jul. 2, 2013, which is a continuation of U.S. patent application Ser. No. 12/484,125, filed Jun. 12, 2009, now U.S. Pat. No. 8,499,757, which claims benefit of priority under 35 U.S.C. § 119(e) from U.S. Provisional Patent Applications Ser. Nos. 61/157,506, filed Mar. 4, 2009, and 61/061,551, filed on Jun. 13, 2008, the contents of each of these applications are incorporated herein by reference in their entirety." Nothing International that I see (only took a quick look, though, and I am not sure what to look for). |
|
|
|
Post by mytakeonit on Jun 16, 2019 21:07:16 GMT -5
Ahhh ... look at the first line in mango's post. Wow, so easy!
But, that's mytakeonit
|
|
|
|
Post by mango on Jul 10, 2019 11:27:43 GMT -5
New MannKind Granted Patent 7/9/2019 Dry powder drug delivery systemAbstract: A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, and a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin and glucagon-like peptide 1 for the treatment of endocrine disease, for example, diabetes and/or obesity. Type: Grant Filed: June 14, 2016 Date of Patent: July 9, 2019 Assignee: MannKind Corporation Inventors: Chad C. Smutney, Benoit Adamo, John M. Polidoro, P. Spencer Kinsey, Dennis Overfield, Carl R. Sahi, Christine Billings, Mark T. Marino patents.justia.com/patent/10342938 |
|
|
|
Post by uflawdog on Jul 10, 2019 12:59:33 GMT -5
It's not international. You can tell because it has a U.S. publication number: ((US20190175848) DRY POWDER INHALER AND SYSTEM FOR DRUG DELIVERY). See here: link. If it issues as a patent, it will provide protection in the U.S. only. The priority date for this family appears to be June 13, 2008, which means that if a patent issues in the U.S., it likely will be valid until June 13, 2028. It is, however, part of a larger family of patent applications (261), which are filed in an impressive number of international jurisdictions (e.g., Australia, Canada, China, Japan, Korea, Mexico, etc). See here: link. A "patent family" does not mean the Mannkind family of patents. Rather, it refers to a subset of Mannkind's patents that share the same specification. Mannkind has many other patents and patent applpications. See here: link. |
|
|
|
Post by robbmo on Jul 10, 2019 14:35:54 GMT -5
It's not international. You can tell because it has a U.S. publication number: ((US20190175848) DRY POWDER INHALER AND SYSTEM FOR DRUG DELIVERY). See here: link. If it issues as a patent, it will provide protection in the U.S. only. The priority date for this family appears to be June 13, 2008, which means that if a patent issues in the U.S., it likely will be valid until June 13, 2028. It is, however, part of a larger family of patent applications (261), which are filed in an impressive number of international jurisdictions (e.g., Australia, Canada, China, Japan, Korea, Mexico, etc). See here: link. A "patent family" does not mean the Mannkind family of patents. Rather, it refers to a subset of Mannkind's patents that share the same specification. Mannkind has many other patents and patent applpications. See here: link. Thank you. This is a very informative post. In reading page 2 of the filing receipt, it looks like a foreign filing license was granted on 2/28/2019, so the international filings may be coming. |
|
|
|
Post by mango on Jul 24, 2019 11:32:15 GMT -5
New MannKind Granted Patent 7/23/2019 Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agentsAbstract: Methods are provided for coating crystalline microparticles with an active agent by altering the surface properties of the microparticles in order to facilitate favorable association on the microparticle by the active agent. Types of surface properties that are altered by the disclosed methods include electrostatic properties, hydrophobic properties, and hydrogen bonding properties. Type: Grant Filed: June 21, 2017 Date of Patent: July 23, 2019 Assignee: MannKind Corporation Inventors: Keith A. Oberg, Joseph Sulner, Marshall L. Grant patents.justia.com/patent/10357459 |
|
|
|
Post by mytakeonit on Jul 24, 2019 11:53:37 GMT -5
Isn't that what I do with wine? If not, then NEVERMIND.
But, that's mytakeonit
|
|
|
|
Post by mango on Aug 13, 2019 14:07:45 GMT -5
Two New MannKind Granted Patents 8/13/2019 1. High capacity diketopiperazine microparticles and methodsAbstract: Disclosed herein are diketopiperazine microparticles having high capacity for adsorbing a drug or active agent. In particular, the diketopiperazine microparticle are formed using fumaryl diketopiperazine and can comprise a drug in large doses for the treatment of disease or disorders by pulmonary delivery via oral inhalation. Type: Grant Filed: October 4, 2018 Date of Patent: August 13, 2019 Assignee: MannKind Corporation Inventors: Marshall Grant, Paul Menkin, Grayson W. Stowell patents.justia.com/patent/103765872. Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agentAbstract: Methods are provided for drying a particle. Specifically, there is provided a spray-dried diketopiperazine-insulin particle formulation having improved aerodynamic performance and in which the active agent is more stabile and efficiently delivered as compared to that of the lyophilized diketopiperazine-insulin formulation. The dry powders have utility as pharmaceutical formulations for pulmonary delivery. Type: Grant Filed: October 4, 2018 Date of Patent: August 13, 2019 Assignee: MannKind Corporation Inventors: Bryan R. Wilson, Marshall Grant patents.justia.com/patent/10376466 |
|
|
|
Post by mango on Sept 7, 2019 12:23:28 GMT -5
|
|
|
|
Post by mango on Sept 13, 2019 10:47:25 GMT -5
|
|
|
|
Post by Clement on Sept 13, 2019 12:02:13 GMT -5
Triptans are serotonin receptor agonists. Step by little step, Mannkind makes progress with MC's pipeline.
|
|
